Aligos Therapeutics Analyst Ratings
Aligos Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest Aligos Therapeutics (ALGS) rating was a maintained with a price target of $3.00 to $7.00. The current price Aligos Therapeutics (ALGS) is trading at is $1.64, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/17/2023 | 326.83% | Piper Sandler | $3 → $7 | Maintains | Overweight |
| 01/06/2023 | 82.93% | Piper Sandler | $2 → $3 | Upgrades | Neutral → Overweight |
| 01/06/2023 | 82.93% | Jefferies | $2.5 → $3 | Upgrades | Hold → Buy |
| 11/03/2022 | 21.95% | SVB Leerink | $3 → $2 | Maintains | Market Perform |
| 05/05/2022 | 82.93% | SVB Leerink | $7 → $3 | Downgrades | Outperform → Market Perform |
| 03/23/2022 | 326.83% | SVB Leerink | $11 → $7 | Maintains | Outperform |
| 03/23/2022 | 143.9% | Piper Sandler | $15 → $4 | Downgrades | Overweight → Neutral |
| 03/11/2022 | 814.63% | Piper Sandler | $47 → $15 | Maintains | Overweight |
| 03/11/2022 | 570.73% | SVB Leerink | $10 → $11 | Maintains | Outperform |
| 02/16/2022 | 509.76% | SVB Leerink | $15 → $10 | Maintains | Outperform |
| 01/07/2022 | 631.71% | JP Morgan | $30 → $12 | Downgrades | Overweight → Neutral |
| 01/07/2022 | 814.63% | SVB Leerink | $29 → $15 | Maintains | Outperform |
| 09/09/2021 | 1668.29% | SVB Leerink | → $29 | Initiates Coverage On | → Outperform |
| 11/10/2020 | 1485.37% | Jefferies | → $26 | Initiates Coverage On | → Buy |
| 11/10/2020 | 1912.2% | JP Morgan | → $33 | Initiates Coverage On | → Overweight |
| 11/10/2020 | 2034.15% | Piper Sandler | → $35 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 01/17/2023 | 326.83% | 派珀·桑德勒 | $3→$7 | 維護 | 超重 |
| 01/06/2023 | 82.93% | 派珀·桑德勒 | $2→$3 | 升級 | 中性→超重 |
| 01/06/2023 | 82.93% | 傑富瑞 | $2.5→$3 | 升級 | 持有→購買 |
| 11/03/2022 | 21.95% | SVB Leerink | $3→$2 | 維護 | 市場表現 |
| 05/05/2022 | 82.93% | SVB Leerink | $7→$3 | 評級下調 | 跑贏→市場表現 |
| 03/23/2022 | 326.83% | SVB Leerink | $11→$7 | 維護 | 跑贏大盤 |
| 03/23/2022 | 143.9% | 派珀·桑德勒 | $15→$4 | 評級下調 | 超重→中性 |
| 03/11/2022 | 814.63% | 派珀·桑德勒 | $47→$15 | 維護 | 超重 |
| 03/11/2022 | 570.73% | SVB Leerink | $10→$11 | 維護 | 跑贏大盤 |
| 02/16/2022 | 509.76% | SVB Leerink | $15→$10 | 維護 | 跑贏大盤 |
| 01/07/2022 | 631.71% | 摩根大通 | $30→$12 | 評級下調 | 超重→中性 |
| 01/07/2022 | 814.63% | SVB Leerink | $29→$15 | 維護 | 跑贏大盤 |
| 09/09/2021 | 1668.29% | SVB Leerink | →$29 | 開始承保 | →跑贏大盤 |
| 11/10/2020 | 1485.37% | 傑富瑞 | →$26 | 開始承保 | →購買 |
| 11/10/2020 | 1912.2% | 摩根大通 | →$33 | 開始承保 | →超重 |
| 11/10/2020 | 2034.15% | 派珀·桑德勒 | →$35 | 開始承保 | →超重 |
What is the target price for Aligos Therapeutics (ALGS)?
Aligos Treeutics(ALGS)的目標價格是多少？
The latest price target for Aligos Therapeutics (NASDAQ: ALGS) was reported by Piper Sandler on January 17, 2023. The analyst firm set a price target for $7.00 expecting ALGS to rise to within 12 months (a possible 326.83% upside). 10 analyst firms have reported ratings in the last year.
派珀·桑德勒於2023年1月17日報道了Aligos治療公司(納斯達克代碼：ALGS)的最新目標價。這家分析公司將目標價定為7美元，預計alg將在12個月內上漲至(可能上漲326.83%)。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Aligos Therapeutics (ALGS)?
Aligos Treeutics(ALGS)的最新分析師評級是什麼？
The latest analyst rating for Aligos Therapeutics (NASDAQ: ALGS) was provided by Piper Sandler, and Aligos Therapeutics maintained their overweight rating.
派珀·桑德勒提供了對阿裡格斯治療公司(納斯達克代碼：ALGS)的最新分析師評級，阿裡格斯治療公司維持其增持評級。
When is the next analyst rating going to be posted or updated for Aligos Therapeutics (ALGS)?
Aligos Treeutics(ALGS)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aligos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aligos Therapeutics was filed on January 17, 2023 so you should expect the next rating to be made available sometime around January 17, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Aligos Treeutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Aligos治療公司的上一次評級是在2023年1月17日提交的，所以你應該預計下一次評級將在2024年1月17日左右的某個時候提供。
Is the Analyst Rating Aligos Therapeutics (ALGS) correct?
分析師對Aligos Treeutics(ALGS)的評級正確嗎？
While ratings are subjective and will change, the latest Aligos Therapeutics (ALGS) rating was a maintained with a price target of $3.00 to $7.00. The current price Aligos Therapeutics (ALGS) is trading at is $1.64, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Aligos Treeutics(ALGS)評級保持不變，目標價在3.00美元至7.00美元之間。Aligos Treateutics(ALGS)目前的交易價格為1.64美元，超出了分析師的預測範圍。
